CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Ethanol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01996943
NCT01996943N/ACompleted
CompareCT.gov

Investigating the Effects of Ethanol on Atrial Fibrillation Susceptibility and Pathogenesis

University of California, San Francisco·interventional·Posted Nov 27, 2013·Updated Mar 16, 2021

In Brief

A clinical study evaluating Ethanol and Placebo for Atrial Fibrillation and Alcohol. Completed, enrolled 100 participants across 1 site.

Detailed Summary

Atrial fibrillation (AF) is the most common sustained arrhythmia in the United States and it has been associated with ethanol use. Understanding how ethanol affects the electrical properties of the heart and induces AF has important public health implications. The objective of this research is to investigate the mechanistic relationship between ethanol and atrial fibrillation in humans by performing a placebo controlled study looking at the electrical properties of the heart in patients receiving intravenous ethanol or placebo. The investigators hypothesize that ethanol increases the susceptibility of human myocardium to atrial fibrillation through electrophysiologic changes in the atrial myocardium in the acute setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Alcohol
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 27, 2013
Enrollment StartSep 1, 2012
Primary CompletionMay 1, 2019
Study CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 12.6 years ago

Interventions

Ethanoldrug

6% volume/volume ethanol in 0.45% saline solution.

Placebodrug

The placebo with be 0.45% saline solution ("half normal saline").